{"id":"NCT02896192","sponsor":"Rhythm Pharmaceuticals, Inc.","briefTitle":"Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity","officialTitle":"An Open-Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset POMC Deficiency Obesity Due to Bi-Allelic Loss-of-Function POMC or PCSK1 Genetic Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-14","primaryCompletion":"2020-05-25","completion":"2020-05-25","firstPosted":"2016-09-12","resultsPosted":"2023-09-21","lastUpdate":"2023-09-21"},"enrollment":15,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pro-opiomelanocortin (POMC) Deficiency Obesity"],"interventions":[{"type":"DRUG","name":"Setmelanotide","otherNames":["RM-493"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Setmelanotide","type":"EXPERIMENTAL"}],"summary":"To demonstrate statistically significant and clinically meaningful effects of setmelanotide on percent body weight change in participants with pro-opiomelanocortin (POMC) deficiency or proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency obesity due to rare biallelic or loss-of function mutations at the end of 1 year of treatment.","primaryOutcome":{"measure":"Percentage of Participants Who Reached â‰¥10% Weight Loss Threshold After 1 Year (Pivotal Cohort)","timeFrame":"Week 52","effectByArm":[{"arm":"Setmelanotide (Entire Study)","deltaMin":80,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":7,"countries":["United States","Belgium","Canada","France","Germany","Spain","United Kingdom"]},"refs":{"pmids":["33137293"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":15},"commonTop":["Skin Hyperpigmentation","Injection Site Erythema","Injection Site Oedema","Injection Site Pruritus","Headache"]}}